<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134845</url>
  </required_header>
  <id_info>
    <org_study_id>190797</org_study_id>
    <nct_id>NCT04134845</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.</brief_title>
  <official_title>A Randomized Controlled Trial of RyR2 Inhibition With Dantrolene and Susceptibility to Ventricular Arrhythmias in Patients With Structural Heart Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo controlled trial of Dantrolene (N= 84 participants) to&#xD;
      demonstrate the feasibility of using I.V. dantrolene to study the effect of RyR2 inhibition&#xD;
      on cardiac electrophysiology, hemodynamics and ventricular arrhythmia inducibility in&#xD;
      patients with structural heart disease referred for VT ablation. The investigators will also&#xD;
      explore the pharmacokinetic/pharmacodynamic relationship of I.V. dantrolene and it short-term&#xD;
      effect on specific cardiac electrophysiologic and hemodynamic parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis to be tested is that RyR2 hyperactivity in patients with structural heart&#xD;
      disease drives proarrhythmic changes in refractoriness and conduction, and decreases cardiac&#xD;
      contractility, which promotes VT/VF. Dantrolene, a currently available drug that inhibits&#xD;
      RyR2, but has no Na or K channel activity, will be used as a tool to study RyR2 modulation.&#xD;
      The investigators propose a randomized controlled trial of dantrolene versus placebo in&#xD;
      patients with structural heart disease referred for VT ablation to evaluate&#xD;
      electrophysiologic, hemodynamic, and arrhythmia prevention endpoints. Dantrolene's inhibition&#xD;
      of RyR1 will also be studied to define its effect on muscle and respiratory strength in this&#xD;
      clinical population, which will be important if dantrolene is to be considered for&#xD;
      repurposing as an antiarrhythmic drug.&#xD;
&#xD;
      The two aims are:&#xD;
&#xD;
      Aim 1: To conduct a randomized, placebo-controlled trial of dantrolene to study the effect of&#xD;
      RyR inhibition on cardiac electrophysiology, hemodynamics, arrhythmia inducibility, muscle&#xD;
      strength, and respiratory mechanics in patients with structural heart disease referred for VT&#xD;
      ablation.&#xD;
&#xD;
      Aim 2: To explore the pharmacokinetic/pharmacodynamic relationship of I.V. dantrolene and its&#xD;
      short-term effect on cardiac electrophysiology, hemodynamics, and muscle and respiratory&#xD;
      strength.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>84 participants will be randomly assigned in a 2:1 ratio to treatment (dantrolene) or control (placebo). A computer-generated randomization list will be prepared by the study statistician using the stratified permuted block randomization, where block size varies randomly from 4 or 6 to ensure overall balance across treatment arms. Randomization will be stratified by 1) documented CAD with prior infarct, 2) amiodarone use within the past 21 days defined as chronic oral use or &gt;5 grams cumulative, 3) LVEF &lt;35%. Enrollment will be evenly distributed across the two study arms by the stratification factors</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The study statistician will generate the allocation schedule but will remain blinded to the treatment assignment as well as the study staff physician's. The research clinician will not be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Inducibility of sustained VT/VF by standardized ventricular stimulation protocol</measure>
    <time_frame>10 minutes post drug infusion</time_frame>
    <description>Post drug ventricular stimulation with RV ventricular catheter in the RV apex with increasing extra stimuli with planned decrement stimuli by 10 ms to ERP. Outcome is measured as Ventricular inducibility yes/no.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage of inducibility by standardized ventricular stimulation protocol of the sustained VT/VF</measure>
    <time_frame>10 minutes post drug infusion</time_frame>
    <description>measured as ordinal variable for stage of ventricular stimulation protocol;specific step by step V-stim research protocol will be followed with single extra stimuli up to six extra stimuli added to VERP. What stage of Inducible VT will be recorded.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serial heart rate measurements</measure>
    <time_frame>pre drug infusion, 1 minute, 5 minute, 10 minute and 20 minutes post infusion</time_frame>
    <description>Heart rate- BPM</description>
  </other_outcome>
  <other_outcome>
    <measure>Serial Blood pressure measurements</measure>
    <time_frame>pre drug infusion,1minute, 5 minute, 10 minute and 20 minutes post drug infusion</time_frame>
    <description>BP - mmHg</description>
  </other_outcome>
  <other_outcome>
    <measure>Serial arterial O2 sats</measure>
    <time_frame>pre drug, post drug 1 minute, 5 minute, 10 minute and 20 minutes</time_frame>
    <description>O2 sats %, percent of Hgb</description>
  </other_outcome>
  <other_outcome>
    <measure>Serial mixed venous O2 sats- measured from PA catheter</measure>
    <time_frame>pre drug infusion, 1 minute , 5 minute, 10 minute and 20 minutes post drug infusion</time_frame>
    <description>mixed venous O2 sats % percent of Hgb</description>
  </other_outcome>
  <other_outcome>
    <measure>Serial PA measurements</measure>
    <time_frame>pre drug infusion , 1 minute, 5 minute, 10 minute and 20 minutes post drug infusion</time_frame>
    <description>PA- mmHg</description>
  </other_outcome>
  <other_outcome>
    <measure>Serial Pulmonary Cap. Wedge pressure measurements</measure>
    <time_frame>pre drug infusion, 1 minute, 5 minute, 10 minute and 20 minutes post drug infusion</time_frame>
    <description>PCWP- mmHg</description>
  </other_outcome>
  <other_outcome>
    <measure>Per the pharmacokinetics measurements that will be collected and measured offline-drug half life</measure>
    <time_frame>post drug infusion at 5 minutes,10 minutes,15 minutes, 20 minutes, 1-4 hours, 6-12 hours,16-24 hours and optional 28-36 hours</time_frame>
    <description>half-life (h)</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximum observed plasma concentration</measure>
    <time_frame>Post drug infusion at 5 minutes, 10 minutes, 15 minutes, 20 minutes, 1-4 hours, 6-12 hours,16-24 hours and optional 28-36 hours</time_frame>
    <description>Cmax (ng/ml)</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to reach maximum observed plasma concentration</measure>
    <time_frame>Post drug infusion at 5 minutes, 10 minutes, 15 minutes, 20 minutes, 1-4 hours, 6-12 hours,16-24 hours and optional 28-36 hours</time_frame>
    <description>Tmax (h)</description>
  </other_outcome>
  <other_outcome>
    <measure>Area under the concentration-time curve from zero to infinity</measure>
    <time_frame>post drug infusion at 5 minutes, 10 minutes, 15 minutes, 20 minutes, 1-4 hours, 6-12 hours,16-24 hours and optional 28-36 hours</time_frame>
    <description>AUC- h ng/ml</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventricular effective refractory period pre/post Dantrolene</measure>
    <time_frame>pre-drug infusion, post drug infusion at 5 minutes, 10 minutes,15 minutes and 20 minute post-drug</time_frame>
    <description>VERP measured at 500 ms</description>
  </other_outcome>
  <other_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>pre-procedure, during procedure</time_frame>
    <description>Oxygen saturation measured by pulse oximeter, %</description>
  </other_outcome>
  <other_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>pre-procedure, during procedure</time_frame>
    <description>Rate of respiration, respiration per minute</description>
  </other_outcome>
  <other_outcome>
    <measure>Minute Ventilation</measure>
    <time_frame>during procedure</time_frame>
    <description>Ventilator measured L/min of ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Tidal Volume</measure>
    <time_frame>during procedure</time_frame>
    <description>Volume of ventilated air, measured as L/breath</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial Blood Gas - pH</measure>
    <time_frame>pre-procedure, during procedure, two hours post procedure</time_frame>
    <description>Blood gas, obtained from arterial blood supply, pH measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial Blood Gas - pO2</measure>
    <time_frame>Pre-procedure, during procedure, two hours post procedure</time_frame>
    <description>Blood gas, obtained from arterial blood supply, mmHg of O2 concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial Blood Gas - pCO2</measure>
    <time_frame>pre-procedure, during procedure, two hours post procedure</time_frame>
    <description>Blood gas, obtained from arterial blood supply, mmHg of CO2 concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial Blood Gas - base excess</measure>
    <time_frame>pre-procedure, during procedure, two hours post procedure</time_frame>
    <description>Blood gas, obtained from arterial blood supply, mmHg of CO2 concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Muscle Strength</measure>
    <time_frame>pre-procedure, two hours post procedure</time_frame>
    <description>Handgrip strength using a dynamometer; measured in pounds of force</description>
  </other_outcome>
  <other_outcome>
    <measure>Neuromuscular twitch height</measure>
    <time_frame>During procedure, post drug infusion at 0, 5, 10, 15, 20 minutes</time_frame>
    <description>Twitch amplitude; measured as a % of the baseline calibration twitch amplitude (unitless, % change)</description>
  </other_outcome>
  <other_outcome>
    <measure>Respiratory support</measure>
    <time_frame>pre-procedure, during procedure, and two hours post procedure</time_frame>
    <description>Bag/mask ventilation, CPAP, BiPAP, LMA, or tracheal intubation</description>
  </other_outcome>
  <other_outcome>
    <measure>Negative Inspiratory Force</measure>
    <time_frame>pre-procedure and two hours post procedure</time_frame>
    <description>measured in cm H20</description>
  </other_outcome>
  <other_outcome>
    <measure>Neuromuscular train of four</measure>
    <time_frame>pre-procedure, during procedure, post drug infusion at 0, 5, 10, 15, 20 minutes, and continuous</time_frame>
    <description>Train of four stimulation test measured as a % of the fourth stimulation compared to the first (unitless, % change)</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood chemistry</measure>
    <time_frame>pre-procedure, during procedure, two hours post procedure</time_frame>
    <description>Arterial blood concentrations of sodium, chloride, potassium, ionized calcium, bicarbonate, glucose, and lactate measured in SI ) international system of units.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Dantrolene/Ryanodex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dantrolene/Ryanodex; intravenous administration of dantrolene; 1 mg/ kg IV over 3 minute, one time dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dantrolene/Ryanodex</intervention_name>
    <description>muscle relaxant</description>
    <arm_group_label>Dantrolene/Ryanodex</arm_group_label>
    <other_name>Dantrium, Ryanodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Greater than or equal to 18 years of age&#xD;
&#xD;
          -  Able to give written informed consent&#xD;
&#xD;
          -  Referred for catheter-based VT ablation&#xD;
&#xD;
          -  Structural heart disease (cardiomyopathy or RV/LV scar)&#xD;
&#xD;
          -  Permanent pacemaker or implantable cardioverter defibrillator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mechanical ventricular support (e.g. LVAD, ECMO)&#xD;
&#xD;
          -  NYHA class IV heart failure&#xD;
&#xD;
          -  LVEF &lt; 20%&#xD;
&#xD;
          -  Morbid obesity (BMI &gt; 40 kg/m2)&#xD;
&#xD;
          -  Severe renal insufficiency (GFR&lt;30 mL/min)&#xD;
&#xD;
          -  Chronic liver disease (Child Pugh class A-C)&#xD;
&#xD;
          -  Current use of calcium channel blockers&#xD;
&#xD;
          -  Neuromuscular disorder (e.g. muscular dystrophy)&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease or restrictive lung disease requiring oxygen&#xD;
&#xD;
          -  Therapy or history of intubation&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  History of dysphagia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Stevenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Stevenson, MD</last_name>
    <phone>615-322-2318</phone>
    <email>william.g.stevenson@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ben M Shoemaker, MD</last_name>
    <phone>615-322-2319</phone>
    <email>moore.b.shoemaker@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Stevenson, MD</last_name>
      <phone>615-322-2318</phone>
      <email>william.g.stevenson@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Diane Crawford, RN</last_name>
      <phone>615-936-6069</phone>
      <email>diane.m.crawford@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>William Stevenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ben Shoemaker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>William Stevenson</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Ventricul Tachycardia ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dantrolene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

